Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

We came across a bullish thesis on Amgen Inc. (AMGN) on Disruptive analytics’ Substack by Magnus Ofstad. In this article, we ...

Louis Navellier is a prominent American investor, author, and financial analyst, best known for his quantitative approach to ...

Central Coast nonprofits and companies are stepping up to support those impacted by the devastating Los Angeles County wildfires. Thousand Oaks-based biotech giant Amgen announced Jan. 14 that it and ...

AbbVie is a Dividend King with solid growth prospects. Investors have multiple reasons to buy the dip with Amgen. Pfizer's dividend is safer than it might seem. High-yield dividend stocks may not ...

Amgen's strong product portfolio and pipeline developments, including, but not limited to, IMDELLTRA and MariTide, support a "Strong Buy" rating for long-term investors despite upcoming patent ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Amgen (NASDAQ:AMGN) underwent analysis by 11 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. The following table provides a quick overview of their recent ...

To gain a panoramic view of Amgen's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.